Determination of the Optimal Volume of 0.5% Bupivacaine Liposome in Single-Injection Interscalene Brachial Plexus Block: A Bayesian Phase I/II Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500098886

Enrollment

Unknown

Registered

2025-03-14

Start date

2025-03-14

Completion date

Unknown

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemidiaphragmatic paresis

Interventions

Intervention group:Interscalene brachial plexus block

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years and above; 2. ASA classification I-III; 3. Undergoing arthroscopic procedures such as rotator cuff repair, capsular plication, acromioplasty, synovectomy, etc.

Exclusion criteria

Exclusion criteria: 1. History of pulmonary disease; 2. Abnormal coagulation function or coagulation disorders; 3. History of local anesthetic allergy; 4. Infection, damage, or history of neck disease at the site of the block; 5. Pregnancy; 6. Refusal to participate in the study or inability to communicate; 7. Long-term use of opioids; 8. Body mass index >35 kg/m^2; 9. History of nerve injury, paralysis, or palsy.

Design outcomes

Primary

Measure	Time frame
Hemidiaphragmatic paresis;	—

Countries

China

Contacts

Public ContactMingzi An

The First Hospital Of Jiaxing

anmingzizi@163.com+86 180 3519 3080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026